Amsterdam Public Health
-
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
Wajja, A., Nassanga, B., Natukunda, A., Serubanja, J., Tumusiime, J., Akurut, H., Oduru, G., Nassuuna, J., Kabagenyi, J., Morrison, H., Scott, H., Doherty, R. P., Marshall, J. L., Puig, I. C., Cose, S., Kaleebu, P., Webb, E. L., Satti, I., McShane, H., Elliott, A. M., & 1 others, 1 Mar 2024, In: The Lancet Infectious Diseases. 24, 3, p. 285-296 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Wajja, A., Nassanga, B., Natukunda, A., Serubanja, J., Tumusiime, J., Akurut, H., Oduru, G., Nassuuna, J., Kabagenyi, J., Morrison, H., Scott, H., Powell Doherty, R., Marshall, J. L., Cabrera Puig, I., Cose, S., Kaleebu, P. & TB042 Study Team, 1 Feb 2024, In: The Lancet Infectious Diseases. 24, 2, p. e78-e79Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications